Description
Cabenuva (cabotegravir + rilpivirine) is a long-acting injectable medicine used to treat HIV-1 infection in adults who are already virologically suppressed. It combines two antiretroviral drugs — cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Administered once monthly or every two months, Cabenuva provides a convenient alternative to daily oral HIV treatment by maintaining viral suppression with fewer doses.
Reviews
There are no reviews yet.